CTLA4 and prostate carcinoma: Although CTLA-4 is not typically mutated in prostate cancer, its immunoregulatory functions indirectly support tumor progression by weakening anti-tumor immunity, promoting the release of pro-tumorigenic factors, and fostering a microenvironment conducive to angiogenesis, invasion, and metastasis [16,39,40].